Patient Capital Management Q4 2025 13F Holdings and Activity Report

I. Institutional Overview

The scale of the institution, sitting at $2.59 billion, places it in a "sweet spot" of institutional management. It is large enough to command significant resources and access to management teams, yet small enough to remain nimble, allowing it to build meaningful positions in mid-cap companies without causing excessive market impact. The portfolio’s concentration—averaging roughly $64.7 million per holding —suggests that each position is the result of rigorous vetting. When an institution holds only 40 stocks, the "hurdle rate" for a new idea to enter the portfolio is exceptionally high. This concentration indicates a belief that risk is mitigated not through the sheer number of holdings, but through the depth of understanding of each business’s competitive moat, cash flow durability, and valuation margin of safety.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

II. Sector Allocation Analysis

The 24.73% allocation to Healthcare is particularly telling. In a period of economic uncertainty, healthcare often serves as a defensive anchor due to its non-discretionary nature. However, looking at the specific holdings (like Royalty Pharma and Biogen), it is clear that Patient Capital is not just buying "defensive" big pharma; it is buying innovation and cash-flow intellectual property . This suggests a macro judgment that while the broader economy may face headwinds, the structural demand for advanced therapeutics and the consolidation of healthcare royalties will continue to provide alpha.

Perhaps the most contrarian aspect of the portfolio is the 10.50% weight in Technology . In a market dominated by the "Magnificent Seven" and AI euphoria, an 10.5% tech weight is significantly lower than the S&P 500's tech weighting (which often exceeds 30%). This suggests that Patient Capital is wary of the "valuation froth" in the broader tech sector. They are not avoiding tech entirely—as evidenced by their NVIDIA and Alphabet holdings—but they are being extremely selective, preferring to own "tech-enabled" businesses in other sectors (like Amazon in Consumer Discretionary) rather than pure-play software or hardware firms at astronomical multiples.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

III. Top 10 Holdings Deep Dive

Alphabet is the quintessential "Patient Capital" stock. It possesses a near-monopoly in search, a dominant position in video (YouTube), and a rapidly growing cloud business. The investment logic here is likely centered on valuation and AI integration . Compared to other mega-cap tech peers, Alphabet has historically traded at a more reasonable P/E multiple. Patient Capital likely views the "AI threat" to search as overblown, believing instead that Alphabet’s vast data moats and engineering talent will allow it to integrate generative AI in a way that enhances, rather than cannibalizes, its core business. The slight reduction in shares suggests a disciplined rebalancing—taking some profit while maintaining a massive core position to capture long-term compounding.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

IV. Major Buys/Additions

In Q4 2025, Patient Capital’s offensive operations were characterized by a "double-down" on existing high-conviction ideas and a strategic entry into the fintech and payments space. The institution deployed significant capital into names that the broader market may be viewing with skepticism, further reinforcing its contrarian identity.

Where did the money come from? The estimated $57 million recouped from the Alibaba (BABA) reduction and the $27 million from the SoFi (SOFI) reduction almost perfectly offset the new investments in Chime, Biogen, and Fiserv. This is a classic "Strategy Rotation." Patient Capital is selling "Global E-commerce" and "High-Beta Fintech" to buy "Domestic Neobanking" and "Biotech Value." This move reduces the portfolio's exposure to international regulatory risks and high-valuation speculative growth, moving it toward assets with more tangible, idiosyncratic catalysts.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

V. Major Sells and Exits

The selling activity in Q4 2025 reveals where Patient Capital’s "patience" has run out or where it believes the risk-reward profile has fundamentally shifted. The most significant move—the massive reduction in Alibaba—marks a major departure from a long-held thesis.

The common thread among the sells is a reduction in "complexity risk." Patient Capital is moving toward "cleaner" stories—companies where the path to value creation is more direct and less dependent on external macro or political factors. This "portfolio slimming" increases the overall quality and predictability of the fund's future returns.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

VI. Investment Insights and Risk Warnings

Sell Complexity: Exit or reduce positions where the "thesis-to-outcome" path is clouded by geopolitical or macro-regulatory factors. 2. Buy Moats at a Discount: Aggressively add to companies with dominant IP (Mattel) or essential healthcare franchises (Biogen) that are currently out of favor with the market. 3. Embrace the Digital Consumer: Maintain core anchors in Alphabet and Amazon while adding "next-gen" consumer finance (Chime) to capture the evolving way people spend and save. 4. Maintain the Barbell: Keep the "ballast" (Citi, JPMorgan, Alphabet) to provide stability, while using the "offensive" wing (NVIDIA, Biogen, Cruise Lines) to drive alpha.

This section shows only part of the complete report. View the app for the full analysis, position-level detail, and quarter-over-quarter tracking.

Sources and limitations

This report uses public U.S. Securities and Exchange Commission Form 13F disclosures and structured data maintained by 13F Hub. A 13F filing is a quarter-end snapshot of reportable long positions, is normally published with a delay, and does not disclose every short position, cash balance, bond, derivative, or non-U.S. asset.

Narrative content is prepared from the same-period SEC disclosure and 13F Hub structured data, then checked before publication. This material is for research and education, not personalized investment advice.